Apnimed is a speculative biotech trading 54% below its 52-week high with heavy insider buying of $5.2M, but revenue is declining 29%, the sole earnings report was a miss and business quality is weak.
Thesis pillars
- Weak Quality No Moat→Stable
- Heavy Insider Buying↓Deteriorating
- Declining Revenue Lumpy→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026
Apnimed, Inc. (APMD) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $15.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.3): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2).
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA)... Read more
Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $15.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.3): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, high confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: speculative.
Recent developments
No fresh coverage since Sep 21, 2026
Recent Developments — Apnimed, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Monday's Intraday Session — benzinga Sep 21, 2026 neutral
- NEWS Apnimed grants 428,428 stock options to 10 new employees - scanx.trade — scanx.trade Sep 12, 2026 neutral
- NEWS Apnimed Q2 2026 Earnings: Revenue Misses $12.1 Million as One-Time Gains Drive $125.9 Million Profit - technotrenz.com — technotrenz.com Sep 10, 2026 negative
- NEWS Apnimed: What We Know Heading Into The Feb PDUFA (NASDAQ:APMD) - Seeking Alpha — Seeking Alpha Sep 10, 2026 positive
- NEWS APMD SWOT Analysis: Financial Resilience Amidst Challenges Revea - GuruFocus — GuruFocus Sep 9, 2026 neutral
Latest item Sep 21, 2026 · Generated 2026-11-05T12:04:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -29.4% YoY. Growth thesis broken unless recovery story develops.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $15.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.3): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.23. Score 4.5/10, high confidence.
Resistance target: $19.60 (+28.1% upside). Prior stop was $14.23. Stop-loss: $14.23.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Leverage penalty (D/E 1.3): -0.5; Earnings in 6 days (event risk).
Apnimed, Inc. trades at a P/E of 2.1 (forward -3.8). TrendMatrix value score: 5.5/10. Verdict: Sell.
10 analysts rate APMD, with a consensus score of 4.2/5. 3 analysts publish price targets averaging $50.
What does Apnimed, Inc. do?Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that...
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.